IDEXX Laboratories (NASDAQ:IDXX) spotted trading -3.83% off 52-week high price. On the other end, the stock has been noted 42.53% away from the low price over the last 52-weeks. The stock changed -0.04% to recent value of $283.28. The stock transacted 313156 shares during most recent day however it has an average volume of 492.00K shares. The company has 86.48M of outstanding shares and 84.57M shares were floated in the market.
On Feb. 12, 2020, IDEXX Laboratories (NASDAQ:IDXX) released that the Company’s Board of Directors has authorized the repurchase of an additional 5.0 million shares of the Company’s common stock under its ongoing share repurchase program. Repurchases may be made at management’s discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 1.8 million shares remaining under the share repurchase program as of February 7, 2020, pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time.
About IDEXX Laboratories
IDEXX Laboratories is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 9,000 people and offers products to customers in over 175 countries.
Its earnings per share (EPS) expected to touch remained 30.50% for this year while earning per share for the next 5-years is expected to reach at 19.08%. IDXX has a gross margin of 56.70% and an operating margin of 22.00% while its profit margin remained 16.90% for the last 12 months.
According to the most recent quarter its current ratio was 1.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.64% from the mean of 20 days, 5.48% from mean of 50 days SMA and performed 5.44% from mean of 200 days price. Company’s performance for the week was 3.24%, 0.35% for month and YTD performance remained 8.48%.